

JOURNAL-BASED LEARNING EXERCISES



Each article's contents should be read, researched and understood, and you should then come to a decision on each question. The pass mark is 17 out of 20 questions answered correctly. JBL exercises may be completed at any time until the published deadline date. Please select your choice of correct answers and complete the exercises online at: www.ibms.org/cpd/jbl

DEADLINE WEDNESDAY 3 OCTOBER 2018

Idiopathic inflammatory myopathies – a guide to subtypes, diagnostic approach and treatment. Oldroyd A, Lilleker J, Chinoy H. <i>Clin Med (Lond)</i> 2017; 17 (4): 322–8. Assessment No: 070518		Characterisation of the scope and magnitude of biotin interference in susceptible Roche Elecsys competitive and sandwich immunoassays. Trambas C, Lu Z, Yen T, Sikaris K. <i>Ann Clin Biochem</i> 2018; 55 (2): 205–15. Assessment No: 070318	
01	A 9–19% frequency of anti-SSA autoantibodies has been reported in adult PM/DM overlap cases, compared with 14–25% in IIM-non-overlap cases.	01	The binding between biotin and streptavidin is very strong.
02	Immune-mediated necrotising myopathy (IMNM), a rare but severe IIM subtype, is characterised by muscle necrosis and regeneration resulting in proximal muscle weakness.	02	High-dose biotin therapy is rarely used and is likely to become less common in the future.
03	IMNM is also associated with presence of the anti-signal recognition particle autoantibody.	03	Generally, sandwich immunoassays will give lower results when samples contain high levels of biotin.
04	Coexisting IIM and mixed CTD is associated with positivity for anti-U1-snRNP autoantibodies, which confers a poor response to steroid treatment and increases prevalence of myositis.	04	The data in the paper suggest the biotin interference in sandwich immunoassays is independent of analyte concentration.
05	For individuals with moderate disease severity, oral prednisolone at a dose of 5–10 mg/kg/day is recommended.	05	Prolactin levels in samples containing 0.5 mg/L biotin are around 30% of those without biotin spiking.
06	Testing for myositis-specific autoantibodies (MSAs) and myositis-associated autoantibodies (MAAs) can further identify clinical subtype, inform the requirement for further investigations and predict treatment response.	06	A normal female testosterone level would be increased to that associated with PCOS with biotin levels of 500 µg/L.
07	The anti-PM/Scl autoantibody occurs most commonly in patients who have PM with overlapping scleroderma features.	07	Biotin metabolites bind to streptavidin with equal affinity to biotin.
08	Identification of MSA/MAAs can inform diagnosis and risk of secondary organ involvement and cancer development.	08	To assist in the interpretation of these findings, studies of biotin pharmacokinetics are warranted.
09	Dermatomyositis (DM) can be distinguished from PM by its typical cutaneous features, which include Gottron's papules, Gottron's sign, heliotrope rash, V-sign rash, mechanic's hands, shawl sign rash and erythroderma.	09	Biotin therapy or use will only be an issue in a clearly defined group of patients.
10	Patients positive for the anti-Ku autoantibody are more likely to suffer Raynaud's phenomenon, ILD, arthralgia and myositis.	10	Renal insufficiency is likely to exacerbate the effects of biotin therapy.
11	Although a raised CK is sensitive for a diagnosis of an IIM, there are many other causes of a raised CK.	11	It may take about a week for measured anti-TSH receptor antibody levels to return to the true value.
12	Features particular to juvenile DM include cutaneous ulcerations, calcinosis cutis and vasculopathy.	12	This study would be almost impossible to conduct in samples naturally containing high levels of biotin.
13	Gottron's sign consists of red, scaly papules that occur over the dorsal aspect of the metacarpophalangeal, proximal and distal interphalangeal joints, whereas Gottron's papules are the same red, scaly papular rash occurring elsewhere on the body.	13	<i>In vivo</i> indicates experiments that take place in a reaction vessel.
14	25% of anti-synthetase antibodies are Jo-1.	14	The effect on TSH and free T4 does not mimic any common clinical condition.
15	The statin-associated form of IMNM is associated with autoantibodies directed against HMGCR and characteristically improves following withdrawal of the statin.	15	Low-dose biotin supplements are unlikely to mask pregnancy assessed using serum β-hCG measurements.
16	The anti-synthetase syndrome is a particularly severe IIM subtype associated with myositis, ILD and inflammatory symmetrical polyarthritis of the small joints of the hands and feet.	16	Normal plasma biotin levels are around 0.5 µg/L.
17	TIF1 is seen in 3–13% of adult PM/DM with a strong association with cancer.	17	This issue only concerns Roche platform users.
18	Fever, Raynaud's phenomenon and mechanic's hands are also characteristic of the anti-synthetase syndrome.	18	This effect is unlikely to cause any issues with the recommendations for lower troponin levels currently being introduced as an early screen for MI.
19	Treatment with tacrolimus, cyclophosphamide, rituximab, tocilizumab or intravenous immunoglobulin can also be considered under specialist care for more resistant cases.	19	To date, no serious clinical issues have been reported due to this interference.
20	The risk of cancer in the IIMs is between two and seven times higher than in the general population.	20	The effect on PSA is likely to remain clinically insignificant.

REFLECTIVE LEARNING

01	Review the myositis-specific antibodies tested for in your laboratory. How do you make sure you consider those autoantibody profiles that are not tested in your laboratory?	01	Outline a strategy for dealing with this issue in your laboratory and hospital. Would this make any difference if you were serving a regional neurology centre?
02	Critically appraise the differential diagnosis of idiopathic inflammatory myopathies.	02	What other commonly available nutritional supplements and herbal medications can affect endogenous metabolite and therapeutic drug levels?